SeaSpine (NASDAQ:SPNE) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Volatility and Risk
SeaSpine has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500.
This table compares SeaSpine and Sensus Healthcare’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares SeaSpine and Sensus Healthcare’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SeaSpine||$143.44 million||1.43||-$33.52 million||($2.18)||-4.93|
|Sensus Healthcare||$26.43 million||3.97||-$2.02 million||($0.14)||-45.43|
Sensus Healthcare has lower revenue, but higher earnings than SeaSpine. Sensus Healthcare is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
64.7% of SeaSpine shares are held by institutional investors. Comparatively, 9.5% of Sensus Healthcare shares are held by institutional investors. 12.5% of SeaSpine shares are held by insiders. Comparatively, 31.2% of Sensus Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent recommendations for SeaSpine and Sensus Healthcare, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SeaSpine currently has a consensus target price of $21.00, suggesting a potential upside of 95.35%. Sensus Healthcare has a consensus target price of $9.50, suggesting a potential upside of 49.37%. Given SeaSpine’s stronger consensus rating and higher probable upside, equities analysts plainly believe SeaSpine is more favorable than Sensus Healthcare.
SeaSpine Company Profile
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary robotic intraoperative radiation therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.